AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01659099
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: in R-ACBVP or in R-CHOP 375 mg/m² on D1
Trial: NCT01659099
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
Trial: NCT01659099
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in ACBVP 10 mg from D1 to D5
Trial: NCT01659099
Drug: Vindesin
RxNorm normalized name: Vindesina
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in ACBVP 2 mg/m² from D1 to D5
Trial: NCT01659099
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: in CHOP 1,4 mg/m² on D1
Trial: NCT01761773
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
Trial: NCT03826199
Drug: TDF-FTC
RxNorm normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.
Trial: NCT02652416
Drug: BI 1026706
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT00789633
Drug: Masitinib
RxNorm normalized name: masitinib
DrugBank: Masitinib (DB11526)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masitinib at 9 mg/kg/day given orally twice daily
Trial: NCT00660985
Drug: Adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel, 0.3%, 2g, once daily for 30 days
Trial: NCT00660985
Drug: Adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gel, 0.1%, 2g, once daily for 30 days
Trial: NCT00485966
Drug: CX-3543
RxNorm normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 mg/m2 daily x 5 q 21 days
Trial: NCT04185415
Drug: bepranemab
RxNorm normalized name: Bepranemab
DrugBank: Bepranemab (DB17945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bepranemab will be administered in a predefined dosage.~* Pharmaceutical Form: Solution for infusion~* Route of Administration: Intravenous
Trial: NCT00548717
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00548717
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00789633
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine at 1000 mg/m2 by intravenous infusion
Trial: NCT00548717
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01369186
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. bolus injection
Trial: NCT00024011
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00821912
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
Trial: NCT00537407
Drug: Debio 025
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 025 supplied as a 100 mg/mL oral solution
Trial: NCT00537407
Drug: Peg-IFNα2a
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
Trial: NCT00537407
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin supplied as 200 mg tablets
Trial: NCT05643586
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient treated with 180 mg ticagrelor 12 hours before the procedure
Trial: NCT05643586
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient treated with 60 mg prasugrel 12 hours before the procedure
Trial: NCT01302054
Drug: Fesoterodine 8 mg
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
Trial: NCT00847015
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
Trial: NCT00847015
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1,000 mg/m\^2
Trial: NCT00847015
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.
Trial: NCT01028170
Drug: furosemide and hypertonic saline solution
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
Trial: NCT01028170
Drug: furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80-160 mg furosemide (Given over 5 min IV twice a day)
Trial: NCT02063997
Drug: Arhalofenate 600 mg
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 600 mg tablets once daily for 12 weeks
Trial: NCT02063997
Drug: Allopurinol 300 mg
RxNorm normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol 300 mg tablets once daily for 12 weeks
Trial: NCT02063997
Drug: Colchicine 0.6 mg
RxNorm normalized name: colchicine 0.6 MG
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
Trial: NCT02063997
Drug: Arhalofenate 800 mg
RxNorm normalized name: Arhalofenate
DrugBank: Arhalofenate (DB11811)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arhalofenate 800 mg tablets once daily for 12 weeks
Trial: NCT04569994
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose administered s.c.
Trial: NCT02411929
Drug: Unlabeled ertugliflozin for oral use
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 15 mg oral (3 x 5 mg tablets)
Trial: NCT02411929
Drug: 14^C-labeled ertugliflozin for IV use
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Trial: NCT02411929
Drug: 14^C-labeled ertugliflozin for oral use
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14\^C (ie, radiolabeled ertugliflozin)
Trial: NCT01165970
Drug: Glandosane
RxNorm normalized name: Glandosane Lemon
DrugBank: Lemon (DB10538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
Trial: NCT01872442
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib 100mg daily starting at inclusion~If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes \> 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study
Trial: NCT01872442
Drug: Peg-Interferon alpha2b
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 µg weekly starting month 4- month 21
Trial: NCT04498351
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine in 2 ml in total volume of 20 ml The procedure is repeated on the contralateral side.
Trial: NCT04498351
Drug: Dexmedetomidine and magnesium sulphate
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 1 μg/kg dexmedetomidine and 100 mg magnesium sulphate in 2 ml in total volume of 20 ml .~The procedure is repeated on the contralateral side.
Trial: NCT04498351
Drug: magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Spermatic cord block by total of 18ml levobupivacaine 0.5% plus 100 mg magnesium sulphate in 2 ml in total volume of 20 ml
Trial: NCT02132000
Drug: toremifene or tamoxifen
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00028028
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT04149678
Drug: Ozanimod
RxNorm normalized name: Ozanimod
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ozanimod
Trial: NCT04149678
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine
Trial: NCT01873690
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once, 400 mg IV
Trial: NCT00290498
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
Trial: NCT00290498
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm A: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.~Arm B: Vincristine 1.4 mg/m\^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle.
Trial: NCT00290498
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
Trial: NCT00290498
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm B: Cytarabine 3 g/m\^2 by vein over 2 hours every 12 hours X 4 doses on days 3 \& 4, cycle 2 and alternating cycles.
Trial: NCT00290498
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
Trial: NCT03470363
Drug: Sevoflurane Volatile Liquid
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03470363
Drug: Bupivacaine / SUFentanil
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00575874
Drug: Rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Trial: NCT00575874
Drug: rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
Trial: NCT00575874
Drug: rivoglitazone HCl
RxNorm normalized name: Pioglitazone Hydrochloride
DrugBank: Rivoglitazone (DB09200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
Trial: NCT00575874
Drug: pioglitazone HCl
RxNorm normalized name: PIOGLITAZONE HCL
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg capsules once daily for 12 weeks
Trial: NCT00099775
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02616003
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Trial: NCT02641522
Drug: Siltuximab
RxNorm normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single infusion of siltuximab (11 mg/kg)
Trial: NCT01591473
Drug: Poly I:Poly C12U 50 ug
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
Trial: NCT01591473
Drug: Poly I:Poly C12U 200 ug
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
Trial: NCT01591473
Drug: Poly I:Poly C12U 500 ug
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
Trial: NCT01591473
Drug: Poly I:Poly C12U 1250 ug
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
Trial: NCT01591473
Drug: FluMist
RxNorm normalized name: FluMist
DrugBank: Influenza B virus B/Brisbane/60/2008 live (attenuated) antigen (DB11037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FluMist 0.2 ml; 3 doses; nasal administration every 28 days
Trial: NCT00348894
Drug: [S,S]-Reboxetine
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[S,S\]-reboxetine
Trial: NCT00348894
Drug: Any
RxNorm normalized name: Acanya
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any standard of care treatment for DPN
Trial: NCT01856621
Drug: Seretide Diskus
RxNorm normalized name: seractide
DrugBank: Seractide acetate (DB09334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT01856621
Drug: SF Easyhaler
RxNorm normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations as a single dose
Trial: NCT03437200
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.
Trial: NCT03437200
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.
Trial: NCT00908037
Drug: eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: thrombopoietin receptor agonist
Trial: NCT01120431
Drug: Isotonic hydration fluid and recombinant human hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
Trial: NCT00854581
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT00854581
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously during Induction Therapy; orally during Maintenance Therapy in all Phases (1, 2A and 2B).
Trial: NCT01762514
Drug: Amifostine every-other-day regimen
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
Trial: NCT01762514
Drug: Amifostine everyday regimen
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
Trial: NCT00205712
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine without dexmedetomidine
Trial: NCT00205712
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ketamine plus dexmedetomidine
Trial: NCT00112203
Drug: Itopride
RxNorm normalized name: itopride
DrugBank: Itopride (DB04924)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00079378
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00079378
Drug: valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02357420
Drug: Relamorelin
RxNorm normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double blind relamorelin was given subcutaneously BID for 12 weeks.
Trial: NCT00928811
Drug: basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simulect 20 mg intravenously day of transplant and day 4
Trial: NCT00928811
Drug: basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
Trial: NCT03766425
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subconjunctival injection
Trial: NCT03766425
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subconjunctival injection
Trial: NCT02913313
Drug: BMS-986207
RxNorm normalized name: Anti-TIGIT Monoclonal Antibody BMS-986207
DrugBank: Renvistobart (DB19065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04080206
Drug: 188-0551 Spray
RxNorm normalized name: POLOXAMER 188
DrugBank: Poloxamer 188 (DB11333)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice daily for two weeks
Trial: NCT02160067
Drug: Second generation BTDS patch
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02160067
Drug: First generation BuTrans patch
RxNorm normalized name: BuTrans
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02460341
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron 8mg, 16mg, 24mg
Trial: NCT04218396
Drug: Standard Treatment during painful bedside procedure
RxNorm normalized name: Bedside-Care
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacologic sedation or high dose opioids (e.g. nurse-administered IV opioids, anxiolytics and sedatives, patient-controlled analgesia, anesthesiologist administered sedation, general anesthesia if required)
Trial: NCT02739516
Drug: Human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
Trial: NCT02739516
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.